A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors
Unknown Phase 1 NCT04362748
Study Description
To evaluate the safety and tolerability of AMG 256 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Study Details
- Registry ID:
- NCT04362748
- Conditions:
- Advanced Solid Tumors
- Phase:
- Phase 1
- Target Enrollment:
- 34 participants
- Start Date:
- Age Range:
- 18–100 years
- Healthy Volunteers:
- No
Study Locations (21 sites)
-
Hospital Clinic i Provincial de Barcelona
Barcelona, Cataluña, Spain -
Hospital Universitari Vall d Hebron
Barcelona, Cataluña, Spain -
Hospital Clinic i Provincial de Barcelona
Barcelona, Catalonia, Spain -
Hospital Universitari Vall d Hebron
Barcelona, Catalonia, Spain -
Hospital Universitari Vall d Hebron
Barcelona, Cataluna, Spain -
Hospital Clinic i Provincial de Barcelona
Barcelona, Cataluna, Spain -
Cliniques Universitaires Saint Luc
Bruxelles, Belgium -
Cliniques Universitaires Saint Luc
Bruxelles, Belgium -
Cliniques Universitaires Saint Luc
Bruxelles, Belgium -
Universitair Ziekenhuis Gent
Ghent, Belgium -
Universitair Ziekenhuis Gent
Gent, Belgium -
Universitair Ziekenhuis Gent
Gent, East Flanders, Belgium -
Indiana University
Indianapolis, Indiana, United States -
Washington University
Saint Louis, Missouri, United States -
Washington University
Saint Louis, Missouri, United States -
Washington University
St Louis, Missouri, United States -
University of Texas MD Anderson Cancer Center
Houston, Texas, United States -
City of Hope National Medical Center
Duarte, California, United States -
Monash Medical Centre
Clayton, Victoria, Australia -
Chris OBrien Lifehouse
Camperdown, New South Wales, Australia -
St Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.